Capricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $77.00 price target on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 481.79% from the stock’s current price.

Capricor Therapeutics Stock Up 0.0 %

Capricor Therapeutics stock traded up $0.01 during trading hours on Monday, hitting $13.24. The stock had a trading volume of 477,640 shares, compared to its average volume of 1,359,141. The stock has a market cap of $601.80 million, a price-to-earnings ratio of -12.47 and a beta of 4.10. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The business’s 50 day simple moving average is $14.18 and its 200-day simple moving average is $14.41.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after purchasing an additional 700,243 shares during the period. Farallon Capital Management LLC purchased a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $31,056,000. Geode Capital Management LLC boosted its position in shares of Capricor Therapeutics by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock valued at $12,139,000 after buying an additional 241,279 shares during the last quarter. Altium Capital Management LLC lifted its holdings in Capricor Therapeutics by 150.5% during the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after acquiring an additional 429,000 shares during the period. Finally, Woodline Partners LP bought a new stake in Capricor Therapeutics during the fourth quarter worth $8,693,000. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.